Comparison of the transdermal delivery of estradiol from two gel formulations

被引:41
作者
Walters, KA
Brain, KR
Green, DM
James, VJ
Watkinson, AC
Sands, RH
机构
[1] AneX Analyt Serv Ltd, Cardiff CF1 3XF, S Glam, Wales
[2] Organon Labs, Cambridge, England
关键词
transdermal drug delivery; hormone replacement therapy; menopause; estradiol;
D O I
10.1016/S0378-5122(98)00009-7
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: Conventional oral oestrogen replacement therapy can relieve postmenopausal symptoms but is associated with undesirable side-effects which can be minimised by avoiding the fluctuating hormonal blood levels resulting from oral therapy and eliminating hepatic first-pass metabolism by the use of the transdermal route. The two commercially available transdermal gel formulations differ in composition and application recommendations. Sandrena Gel contains 0.1% (w/w) and Oestrogel 0.06% (w/w) estradiol and recommended dosages an 0.5-1.5 g over 200-400 cm(2) (Sandrena Gel) and 2.5 g gel over 720 cm(2) (Oestrogel). In transdermal therapy the formulation composition may have a significant effect on drug delivery and we have therefore compared the permeation of estradiol from these formulations across human skin in vitro. Methods: The in vitro percutaneous penetration of estradiol from the formulations through epidermal membranes prepared from excised female human thigh skin was assessed over a 24 h period using static type Franz diffusion cells. Results: Permeation of the active was similar from each formulation representing (at 24 h) 18.2 +/- 3.5% of the applied dose from Sandrena Gel and 17.4 +/- 4.8% of the applied dose from Oestrogel. These percentages equate to cumulative skin permeations of 0.65 +/- 0.15 mu g/cm(2) and 0.45 +/- 0.15 mu g/cm(2) respectively. Conclusion: The results suggest that the two formulations are bioequivalent at the recommended dose levels. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 26 条
[11]  
GOOD W R, 1985, Journal of Controlled Release, V2, P89, DOI 10.1016/0168-3659(85)90035-5
[12]   EFFECT OF PGML EXCIPIENT MIXTURE IN A TRANSDERMAL SYSTEM ON THE IN-VITRO TRANSPORT OF ESTRADIOL ACROSS SKIN [J].
IRION, GD ;
GARRISON, MD ;
ABRAHAM, W .
PHARMACEUTICAL RESEARCH, 1995, 12 (11) :1618-1622
[13]   BIOAVAILABILITY STUDY OF MENOREST(R), A NEW ESTROGEN TRANSDERMAL DELIVERY SYSTEM, COMPARED WITH A TRANSDERMAL RESERVOIR SYSTEM [J].
LEROUX, Y ;
BORG, ML ;
SIBILLE, M ;
THEBAULT, J ;
RENOUX, A ;
DOUIN, MJ ;
DJEBBAR, F ;
DAIN, MP .
CLINICAL DRUG INVESTIGATION, 1995, 10 (03) :172-178
[14]   TRANSPORT OF BETA-ESTRADIOL IN FRESHLY EXCISED HUMAN SKIN IN-VITRO - DIFFUSION AND METABOLISM IN EACH SKIN LAYER [J].
LIU, PC ;
HIGUCHI, WI ;
GHANEM, AH ;
GOOD, WR .
PHARMACEUTICAL RESEARCH, 1994, 11 (12) :1777-1784
[15]   COTRANSPORT OF ESTRADIOL AND ETHANOL THROUGH HUMAN SKIN INVITRO - UNDERSTANDING THE PERMEANT ENHANCER FLUX RELATIONSHIP [J].
LIU, PC ;
KURIHARABERGSTROM, T ;
GOOD, WR .
PHARMACEUTICAL RESEARCH, 1991, 8 (07) :938-944
[16]   TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH TRANSDERMAL ESTROGEN [J].
LUFKIN, EG ;
WAHNER, HW ;
OFALLON, WM ;
HODGSON, SF ;
KOTOWICZ, MA ;
LANE, AW ;
JUDD, HL ;
CAPLAN, RH ;
RIGGS, BL .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (01) :1-9
[17]   VEHICLE DESIGN FOR A NEW TOPICAL STEROID, FLUOCINONIDE [J].
OSTRENGA, J ;
HALEBLIAN, J ;
POULSEN, B ;
FERRELL, B ;
MUELLER, N ;
SHASTRI, S .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1971, 56 (05) :392-+
[18]   PHARMACOKINETICS AND PHARMACODYNAMICS OF TRANSDERMAL DOSAGE FORMS OF 17-BETA-ESTRADIOL - COMPARISON WITH CONVENTIONAL ORAL ESTROGENS USED FOR HORMONE REPLACEMENT [J].
POWERS, MS ;
SCHENKEL, L ;
DARLEY, PE ;
GOOD, WR ;
BALESTRA, JC ;
PLACE, VA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1985, 152 (08) :1099-1106
[19]   INVIVO PERCUTANEOUS PENETRATION OF SOME ORGANIC-COMPOUNDS RELATED TO ANATOMIC SITE IN HUMANS - PREDICTIVE ASSESSMENT BY THE STRIPPING METHOD [J].
ROUGIER, A ;
LOTTE, C ;
MAIBACH, HI .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (06) :451-454
[20]   FDA AND AAPS REPORT OF THE WORKSHOP ON PRINCIPLES AND PRACTICES OF INVITRO PERCUTANEOUS PENETRATION STUDIES - RELEVANCE TO BIOAVAILABILITY AND BIOEQUIVALENCE [J].
SKELLY, JP ;
SHAH, VP ;
MAIBACH, HI ;
GUY, RH ;
WESTER, RC ;
FLYNN, G ;
YACOBI, A .
PHARMACEUTICAL RESEARCH, 1987, 4 (03) :265-267